Chronic lymphocytic leukemia therapy: new targeted therapies on the way

Keyphrases

• New Targeted Therapy 100%
• Chronic Lymphocytic Leukemia 100%
• Leukemia Therapy 100%
• B-cell Receptor Signaling 42%
• New Drugs 28%
• Leukemia Patients 14%
• Clinical Data 14%
• High Risk 14%
• CD20 14%
• I to 14%
• Clinical Efficacy 14%
• Mechanism of Action 14%
• New Agents 14%
• B-cell Lymphoma 2 (Bcl-2) 14%
• Chronic Lymphocytic Leukemia Cells 14%
• Preclinical Data 14%
• Cell Surface 14%
• Expert Opinion 14%
• Targeted Agents 14%
• PubMed 14%
• Chemoimmunotherapy 14%
• Relapsed Disease 14%
• Tissue Microenvironment 14%
• Armamentarium 14%
• Ibrutinib 14%
• Idelalisib 14%
• Area Cover 14%
• Late Development 14%
• Side Effect Profile 14%
• Obinutuzumab 14%
• Direct Targeting 14%
• Peer-reviewed Articles 14%
• International Meeting 14%
• Heterogeneous Mechanism 14%
• New Targeted Drugs 14%
• Venetoclax 14%

Medicine and Dentistry

• Targeted Therapy 100%
• B-Cell Chronic Lymphocytic Leukemia 100%
• B Lymphocyte Receptor 37%
• Diseases 12%
• Side Effect 12%
• CD20 12%
• Leukemia Cell 12%
• Cell Surface 12%
• Chemoimmunotherapy 12%
• Ibrutinib 12%
• Idelalisib 12%
• Obinutuzumab 12%
• Venetoclax 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Lymphatic Leukemia 100%
• B Lymphocyte Receptor 37%
• Diseases 12%
• Side Effect 12%
• Immunotherapy 12%
• Idelalisib 12%
• Ibrutinib 12%
• Obinutuzumab 12%
• Venetoclax 12%